AU · rank #2 · 2026-07-21
DIA
GPW · PLN · $1.52B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.271 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | -$0.38 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $204.28 | +17.9% |
| Momentum acceleration 3-month minus 12-month momentum. | +13.92% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.33 |
| Gross margin TTM | +79.3% |
| 52w high | $214.46 |
| Market cap (USD) | $1.52B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Diagnostyka S.A. is Poland’s leading medical diagnostics network, operating 150+ labs and 1,100+ collection points across a national hub-and-spoke platform for lab, imaging, and preventive testing.
Rationale
The analyst-upside setup is supported by a 17.9% target-price upside, a strong average analyst rating, unanimous revision agreement, and improving share momentum, while Q1 2026 results showed mid-teens revenue and profit growth.
Material risks
- 1Polish reimbursement or pricing changes could hit test volumes and margins across DIA’s highly exposed domestic healthcare footprint.
- 2Hospitals and universities insourcing diagnostics, or point-of-care/home testing taking routine volume, could erode Diagnostyka’s network-driven demand.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.